Active substance | Sofosbuvir + Velpatasvir |
US Brand | Generic Epclusa |
IN Brand | Sofosvel | Velpanat | Velasof |
Manufacturing by | Beacon | Natco | Hetero |
Strength | 400mg + 100mg |
Form release | blister 6 tabs | bottle 28 tabs |
Estimated shipping time | 7 – 18 days (Depending from the Country) |
Availability, Prices & Order | through request form |
Sofosbuvir-velpatasvir is the first available pangenotypic NS5A-NS5B inhibitor single-pill combination regimen, and is highly efficacious across HCV genotypes 1 to 6. It provides a much-needed interferon-free option for patients with genotype 3 infection that is more economical than sofosbuvir plus daclatasvir, and in patients who have compensated cirrhosis with genotype 3, this single-pill option provides an important ribavirin-free combination that will prove a welcome alternative to what has been available to date. Notably, unlike ledipasvir-sofosbuvir, an abbreviated duration of 8 weeks has not been studied with sofosbuvir-velpatasvir for any of the genotypes, except in conjunction with a third agent (GS-9857, an investigational pangenotypic HCV protease inhibitor). Sofosbuvir-velpatasvir, like ledipasvir-sofosbuvir, will be susceptible to drug interactions with acid-reducing agents particularly proton-pump inhibitors and the impact of these agents on real-world clinical effectiveness remains to be determined.
http://www.hepatitisc.uw.edu/page/treatment/drugs/epclusa
RECOMMENDED DOSAGE
The recommended dosage of Sofosvel/Velpanat is one tablet taken orally once daily with or without food [see Clinical Pharmacology (12.3)]. One tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Table 1 shows the recommended treatment regimen and duration based on patient population.
Patient Population | Treatment Regimen and Duration |
---|---|
Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A) | Sofosvel/Velpanat 12 weeks |
Patients with decompensated cirrhosis (Child-Pugh B or C) | Sofosvel/Velpanat + ribavirin* 12 weeks |
|
NO DOSAGE RECOMMENDATIONS IN SEVERE RENAL IMPAIRMENT AND END STAGE RENAL DISEASE
No dosage recommendation can be given for patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min/1.73 m2) or with end stage renal disease (ESRD), due to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Common side effects (in more than 10% of people) are headache, fatigue and nausea.